CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the appointment of Colin Sandercock as Senior Vice President and General Counsel.
Sandercock brings more than 30 years of experience advising life sciences companies on a broad range of legal matters, including domestic and international patent litigation, compliance, procurement, and licensing.
“Colin brings deep legal expertise and life sciences experience to the company, adding further strength to our executive team,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. “Colin’s addition comes at an ideal time, as we continue to advance our promising pipeline of immuno-oncology drugs, exemplified by our lead program, CUE-101, for the treatment of HPV-driven cancers, as well as our therapeutics targeting autoimmune diseases.”
Before joining Cue Biopharma, Sandercock was most recently a Partner at Perkins Coie since 2009. Prior to Perkins Coie, he held positions within legal firms including Proskauer Rose where he co-chaired the firm’s Life Science Practice Group; Heller Ehrman, where he co-chaired the firm’s Intellectual Property Practice Group; and Foley & Lardner, where he chaired the firm’s Chemical Practice Group. His technical experience includes life science, pharmaceutical compositions and biologics, organic and inorganic chemistries, as well as chemical and biochemical engineering. Sandercock has served as an adjunct professor of law at George Washington University Law School, lecturing on the licensing of intellectual property rights, and on the AAA Patent Advisory Committee for Patent Disputes. He received his J.D. from the Catholic University of America and received a M.Sc. in Engineering degree in Chemical and Biochemical Engineering from the University of Pennsylvania, and a B.S. in Chemistry and Mathematics from Moravian College.
About CUE-101
CUE-101 is a fusion of a variant form of the cytokine Interleukin-2 (“IL-2”) and a pMHC derived from the human papilloma virus E7 protein (HPV-E7). It is a single, covalently-assembled biologic designed to target and activate T cells specific to HPV-driven cancers. We believe CUE-101 offers significant advantages over current therapies and has the potential to provide patients with a more effective and safer alternative in treating HPV-driven cancers. Our preclinical data, including animal models of HPV- positive cancer, have generated highly encouraging results supporting strong efficacy as a monotherapy and synergy with approved checkpoint therapies.
About Cue Biopharma
Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.
We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs.
Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.
